"Global Immunotherapy Drugs Market Overview:
Global Immunotherapy Drugs Market is expected to grow at a significant rate during the forecast period 2025-2032, with 2024 as the base year.
Global Immunotherapy Drugs Market Report 2025 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2025-2032.This research study of Immunotherapy Drugs involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Immunotherapy Drugs Market:
The Immunotherapy Drugs Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Immunotherapy Drugs Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Immunotherapy Drugs Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Immunotherapy Drugs market has been segmented into:
Immune checkpoint inhibitors
Monoclonal antibodies
Vaccines
Adoptive Cell Therapies
Immune System Modulators
Oncolytic Virus Therapy
By Application, Immunotherapy Drugs market has been segmented into:
Intravenous
Oral
Intramuscular
Subcutaneous
Others
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Immunotherapy Drugs market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Immunotherapy Drugs market.
Top Key Players Covered in Immunotherapy Drugs market are:
Bristol-Myers Squibb Company
Pfizer Inc
Novartis AG
Merck & Co.inc.
AstraZeneca
Amgen Inc.
GSK plc.
Gilead Sciencesinc.
Johnson & Johnson
Actym Therapeuticsinc.
Fate Therapeutics .
Gritstone bioincyte
Acumen Pharmaceuticalsinc
Arcus Biosciencesinc.
immunitybio inc
Autolus Therapeutics
ADC Therapeutics SA.
BioNTech SE
Cellectis
"
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Immunotherapy Drugs Market by Type
4.1 Immunotherapy Drugs Market Snapshot and Growth Engine
4.2 Immunotherapy Drugs Market Overview
4.3 Immune checkpoint inhibitors
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Immune checkpoint inhibitors: Geographic Segmentation Analysis
4.4 Monoclonal antibodies
4.4.1 Introduction and Market Overview
4.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.4.3 Key Market Trends, Growth Factors and Opportunities
4.4.4 Monoclonal antibodies: Geographic Segmentation Analysis
4.5 Vaccines
4.5.1 Introduction and Market Overview
4.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.5.3 Key Market Trends, Growth Factors and Opportunities
4.5.4 Vaccines: Geographic Segmentation Analysis
4.6 Adoptive Cell Therapies
4.6.1 Introduction and Market Overview
4.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.6.3 Key Market Trends, Growth Factors and Opportunities
4.6.4 Adoptive Cell Therapies: Geographic Segmentation Analysis
4.7 Immune System Modulators
4.7.1 Introduction and Market Overview
4.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.7.3 Key Market Trends, Growth Factors and Opportunities
4.7.4 Immune System Modulators: Geographic Segmentation Analysis
4.8 Oncolytic Virus Therapy
4.8.1 Introduction and Market Overview
4.8.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
4.8.3 Key Market Trends, Growth Factors and Opportunities
4.8.4 Oncolytic Virus Therapy: Geographic Segmentation Analysis
Chapter 5: Immunotherapy Drugs Market by Application
5.1 Immunotherapy Drugs Market Snapshot and Growth Engine
5.2 Immunotherapy Drugs Market Overview
5.3 Intravenous
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Intravenous: Geographic Segmentation Analysis
5.4 Oral
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Oral: Geographic Segmentation Analysis
5.5 Intramuscular
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Intramuscular: Geographic Segmentation Analysis
5.6 Subcutaneous
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Subcutaneous: Geographic Segmentation Analysis
5.7 Others
5.7.1 Introduction and Market Overview
5.7.2 Historic and Forecasted Market Size in Value USD and Volume Units (2017-2032F)
5.7.3 Key Market Trends, Growth Factors and Opportunities
5.7.4 Others: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Immunotherapy Drugs Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 BRISTOL-MYERS SQUIBB COMPANY
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 PFIZER INC
6.4 NOVARTIS AG
6.5 MERCK & CO.INC.
6.6 ASTRAZENECA
6.7 AMGEN INC.
6.8 GSK PLC.
6.9 GILEAD SCIENCESINC.
6.10 JOHNSON & JOHNSON
6.11 ACTYM THERAPEUTICSINC.
6.12 FATE THERAPEUTICS .
6.13 GRITSTONE BIOINCYTE
6.14 ACUMEN PHARMACEUTICALSINC
6.15 ARCUS BIOSCIENCESINC.
6.16 IMMUNITYBIO INC
6.17 AUTOLUS THERAPEUTICS
6.18 ADC THERAPEUTICS SA.
6.19 BIONTECH SE
6.20 CELLECTIS
Chapter 7: Global Immunotherapy Drugs Market By Region
7.1 Overview
7.2. North America Immunotherapy Drugs Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Immune checkpoint inhibitors
7.2.4.2 Monoclonal antibodies
7.2.4.3 Vaccines
7.2.4.4 Adoptive Cell Therapies
7.2.4.5 Immune System Modulators
7.2.4.6 Oncolytic Virus Therapy
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Intravenous
7.2.5.2 Oral
7.2.5.3 Intramuscular
7.2.5.4 Subcutaneous
7.2.5.5 Others
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Immunotherapy Drugs Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Immune checkpoint inhibitors
7.3.4.2 Monoclonal antibodies
7.3.4.3 Vaccines
7.3.4.4 Adoptive Cell Therapies
7.3.4.5 Immune System Modulators
7.3.4.6 Oncolytic Virus Therapy
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Intravenous
7.3.5.2 Oral
7.3.5.3 Intramuscular
7.3.5.4 Subcutaneous
7.3.5.5 Others
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Immunotherapy Drugs Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Immune checkpoint inhibitors
7.4.4.2 Monoclonal antibodies
7.4.4.3 Vaccines
7.4.4.4 Adoptive Cell Therapies
7.4.4.5 Immune System Modulators
7.4.4.6 Oncolytic Virus Therapy
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Intravenous
7.4.5.2 Oral
7.4.5.3 Intramuscular
7.4.5.4 Subcutaneous
7.4.5.5 Others
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Immunotherapy Drugs Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Immune checkpoint inhibitors
7.5.4.2 Monoclonal antibodies
7.5.4.3 Vaccines
7.5.4.4 Adoptive Cell Therapies
7.5.4.5 Immune System Modulators
7.5.4.6 Oncolytic Virus Therapy
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Intravenous
7.5.5.2 Oral
7.5.5.3 Intramuscular
7.5.5.4 Subcutaneous
7.5.5.5 Others
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Immunotherapy Drugs Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Immune checkpoint inhibitors
7.6.4.2 Monoclonal antibodies
7.6.4.3 Vaccines
7.6.4.4 Adoptive Cell Therapies
7.6.4.5 Immune System Modulators
7.6.4.6 Oncolytic Virus Therapy
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Intravenous
7.6.5.2 Oral
7.6.5.3 Intramuscular
7.6.5.4 Subcutaneous
7.6.5.5 Others
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Immunotherapy Drugs Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Immune checkpoint inhibitors
7.7.4.2 Monoclonal antibodies
7.7.4.3 Vaccines
7.7.4.4 Adoptive Cell Therapies
7.7.4.5 Immune System Modulators
7.7.4.6 Oncolytic Virus Therapy
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Intravenous
7.7.5.2 Oral
7.7.5.3 Intramuscular
7.7.5.4 Subcutaneous
7.7.5.5 Others
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Immunotherapy Drugs Scope:
|
Report Data
|
Immunotherapy Drugs Market
|
|
Immunotherapy Drugs Market Size in 2025
|
USD XX million
|
|
Immunotherapy Drugs CAGR 2025 - 2032
|
XX%
|
|
Immunotherapy Drugs Base Year
|
2024
|
|
Immunotherapy Drugs Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Bristol-Myers Squibb Company, Pfizer Inc, Novartis AG, Merck & Co.inc., AstraZeneca, Amgen Inc., GSK plc., Gilead Sciencesinc., Johnson & Johnson, Actym Therapeuticsinc., Fate Therapeutics ., Gritstone bioincyte, Acumen Pharmaceuticalsinc, Arcus Biosciencesinc., immunitybio inc, Autolus Therapeutics, ADC Therapeutics SA., BioNTech SE, Cellectis.
|
|
Key Segments
|
By Type
Immune checkpoint inhibitors
Monoclonal antibodies
Vaccines
Adoptive Cell Therapies
Immune System Modulators
Oncolytic Virus Therapy
By Applications
Intravenous
Oral
Intramuscular
Subcutaneous
Others
|
